<DOC>
	<DOCNO>NCT02718300</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , efficacy combination INCB050465 ruxolitinib subject myelofibrosis .</brief_summary>
	<brief_title>A Study INCB050465 Combination With Ruxolitinib Subjects With Myelofibrosis</brief_title>
	<detailed_description />
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<criteria>Diagnosis primary myelofibrosis , postpolycythemia vera myelofibrosis , postessential thrombocythemia myelofibrosis Palpable spleen &gt; 10 cm leave subcostal margin physical examination screen visit OR Palpable splenomegaly 5 10 cm leave subcostal margin physical exam AND active symptom MF screen visit demonstrate presence 1 symptom score ≥ 5 2 symptom score ≥ 3 use Screening Symptom Form Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 Use experimental drug therapy myelofibrosis , standard drug ( eg , danazol , hydroxyurea , etc ) exception ruxolitinib within 6 month start study ( combination ) therapy and/or lack recovery toxicities previous therapy ( except ruxolitinib ) Grade 1 good Inability swallow food condition upper gastrointestinal tract precludes administration oral medication Unwillingness transfuse blood component Recent history inadequate bone marrow reserve demonstrate follow : Platelet count &lt; 50 × 10^9/L 4 week screen platelet transfusion ( ) within 8 week screen Absolute neutrophil count level &lt; 0.5 × 10^9/L 4 week screen Subjects peripheral blood blast count &gt; 10 % screen baseline hematology assessment Subjects willing receive red blood cell ( RBC ) transfusion treat low hemoglobin level Inadequate liver function screen baseline visit demonstrate follow : Direct bilirubin ≥ 2.0 × upper limit laboratory normal ( ULN ) . ( NOTE : direct bilirubin determine total bilirubin ≥ 2.0 × ULN ) alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 2.5 × ULN Inadequate renal function screen baseline visit demonstrate creatinine clearance &lt; 50 mL/min glomerular filtration rate &lt; 50 mL/min/1.73 m^2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Primary myelofibrosis ( PMF )</keyword>
	<keyword>post-polycythemia vera myelofibrosis ( PPV-MF )</keyword>
	<keyword>post-essential thrombocythemia myelofibrosis ( PET-MF )</keyword>
	<keyword>myeloproliferative neoplasm ( MPNs )</keyword>
	<keyword>phosphoinositide 3-kinase ( PI3K ) inhibitor</keyword>
	<keyword>Janus kinase ( JAK ) inhibitor</keyword>
</DOC>